↓ Skip to main content

Dove Medical Press

Article Metrics

Suvorexant: a promising, novel treatment for insomnia

Overview of attention for article published in Neuropsychiatric Disease and Treatment, February 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter
6 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
20 Mendeley
Title
Suvorexant: a promising, novel treatment for insomnia
Published in
Neuropsychiatric Disease and Treatment, February 2016
DOI 10.2147/ndt.s31495
Pubmed ID
Authors

James Parish, Joyce Lee-Iannotti

Abstract

Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 1 5%
Professor > Associate Professor 1 5%
Unknown 18 90%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 2 10%
Unknown 18 90%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2016.
All research outputs
#3,399,933
of 12,517,383 outputs
Outputs from Neuropsychiatric Disease and Treatment
#512
of 2,120 outputs
Outputs of similar age
#79,091
of 268,399 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#31
of 74 outputs
Altmetric has tracked 12,517,383 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,120 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,399 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 74 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.